

PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)	KANUMA (sebelipase alfa)	
Status: CVS Caremark Criteria		MDC
Type: Initial Prior Authorization		Ref #1314-A

FDA-APPROVED INDICATION¹

Kanuma is indicated for the treatment of patients with a diagnosis of lysosomal acid lipase (LAL) deficiency.

<u>CRITERIA FOR APPROVAL</u>			
1	Does the patient have a diagnosis of lysosomal acid lipase (LAL) deficiency? [If no, no further questions.]	Yes	No
2	Was the diagnosis confirmed by an enzyme assay demonstrating a deficiency of lysosomal acid lipase enzyme activity OR by genetic testing?	Yes	No

Guidelines for Approval	
Duration of Approval	12 Months
Set 1: LAL Deficiency	
Yes to question(s)	No to question(s)
1	None
2	

Mapping Instructions		
	Yes	No
1	Go to 2	Deny
2	Approve, 12 months	Deny

RATIONALE

These criteria meet the Medicare Part D definition of a medically accepted indication. This definition includes uses which are approved by the FDA or supported by a citation included, or approved for inclusion, in one of the Medicare approved compendia.

The intent of the criteria is to ensure that patients follow selection elements noted in labeling and/or practice guidelines in order to decrease the potential for inappropriate utilization.

REFERENCES

1. Kanuma [package insert]. Cheshire, CT: Alexion Pharmaceuticals Inc.; December 2015.

DOCUMENT HISTORY

Written: Specialty Clinical Development (TS) 12/2015
 Revised: DK 04/2016, PK 02/2017, DK 07/2017 (CMS)
 Reviewed: CDPR/LCB 12/2015, LMS 05/2016, LMS 03/2017
 External Review: 12/2015, 07/2016, 05/2017

Kanuma 1314-A MDC 2018 (1).docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.